Citizens Jmp Reaffirms Market Outperform Rating for Opus Genetics (NASDAQ:IRD)

Posted by Brenda Bartman on Oct 16th, 2026

Opus Genetics (NASDAQ:IRD – Get Free Report)‘s stock had its “market outperform” rating restated by stock analysts at Citizens Jmp in a report released on Friday, Benzinga reports. They currently have a $17.00 price objective on the stock. Citizens Jmp’s target price would indicate a potential upside of 342.71% from the stock’s previous close.

Several other analysts also recently commented on IRD. JonesTrading boosted their target price on shares of Opus Genetics from $10.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, October 6th. HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Opus Genetics in a research report on Wednesday, September 9th. Wedbush boosted their target price on shares of Opus Genetics from $10.00 to $13.00 and gave the stock an “outperform” rating in a research report on Thursday, September 10th. BTIG Research reissued a “buy” rating and issued a $12.00 target price on shares of Opus Genetics in a research report on Wednesday, September 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Opus Genetics in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Opus Genetics has an average rating of “Moderate Buy” and a consensus target price of $12.71.

Read Our Latest Report on IRD

Opus Genetics Stock Down 5.2%

IRD stock traded down $0.21 during trading hours on Friday, hitting $3.84. The company’s stock had a trading volume of 2,525,524 shares, compared to its average volume of 1,434,540. The company has a market capitalization of $317.38 million, a PE ratio of -2.84 and a beta of 0.62. Opus Genetics has a 12 month low of $1.70 and a 12 month high of $7.07. The stock has a 50 day moving average price of $4.50 and a two-hundred day moving average price of $4.39.

Opus Genetics (NASDAQ:IRD – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.02. The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $2.63 million. Sell-side analysts expect that Opus Genetics will post -0.97 earnings per share for the current year.

Insider Activity at Opus Genetics

In related news, CEO George Magrath sold 9,475 shares of the company’s stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $2.95, for a total transaction of $27,951.25. Following the completion of the transaction, the chief executive officer directly owned 1,731,869 shares in the company, valued at $5,109,013.55. This represents a 0.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Fighting Blindness Foundation sold 556,000 shares of the stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $4.96, for a total transaction of $2,757,760.00. Following the completion of the transaction, the director owned 3,236,171 shares of the company’s stock, valued at approximately $16,051,408.16. This represents a 14.66% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 613,331 shares of company stock worth $2,971,509 in the last ninety days. 11.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Opus Genetics

A number of institutional investors have recently modified their holdings of the stock. Sanders Morris Harris LLC bought a new position in shares of Opus Genetics in the third quarter worth about $58,000. Opaleye Management Inc. raised its stake in shares of Opus Genetics by 0.4% in the second quarter. Opaleye Management Inc. now owns 1,125,000 shares of the company’s stock worth $4,624,000 after acquiring an additional 5,000 shares during the last quarter. Engineers Gate Manager LP bought a new position in shares of Opus Genetics in the second quarter worth about $50,000. Squarepoint Ops LLC bought a new position in shares of Opus Genetics in the second quarter worth about $1,360,000. Finally, Nantahala Capital Management LLC bought a new position in shares of Opus Genetics in the second quarter worth about $12,582,185. 14.97% of the stock is owned by institutional investors.

About Opus Genetics

(Get Free Report)

Opus Genetics, Inc is a clinical-stage biotechnology company focused on developing gene therapies for inherited retinal diseases, a group of rare disorders that can cause progressive vision loss and blindness. The company’s research is centered on therapies intended to address the underlying genetic causes of these conditions rather than treating only their symptoms.

Opus Genetics is advancing an investigational pipeline of adeno-associated virus-based gene therapy candidates for diseases involving mutations in genes important to retinal function.